Company profile
Horizon Space Acquisition II Corp.
NASDAQ: SLBT · Healthcare · Biotechnology
#782 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH 42DQ —GM —SS 20
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, market scale · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
$2.2M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.8M
Employees
2
as of 2026-08-02
Market cap
$20.9M
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.2M$2.2M2025
Net income-$3.8M-$3.8M2025
Operating income-$3.8M-$3.8M2025
Total assets$2.8M$2.8M2025
Liabilities$533.3k$533.3k2025
Equity$2.3M$2.3M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Horizon Space Acquisition II Corp.’s revenue?
Horizon Space Acquisition II Corp. booked $2.2M in FY2025 revenue, contracting 35% year over year — slower than 77% of Healthcare companies we track, at a -173.8% net margin.
Peers · Healthcare
Elicio Therapeutics, Inc.24DFemasys Inc.41DAdynxx, Inc.——Aligos Therapeutics, Inc.47DAmerican Mobile Dental Corp.——Endexx Corporation——Neighbors
New York →Key facts
CEOMingyu Li
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York, NY
ExchangeNASDAQ: SLBT
Employees2
IPO date2025-02-05
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.